Skip to main content
. Author manuscript; available in PMC: 2019 Jan 9.
Published in final edited form as: Nat Med. 2018 Jul 9;24(9):1324–1329. doi: 10.1038/s41591-018-0103-x

Figure 2. eGluCl reduces acute chemoconvulsant-induced seizures.

Figure 2

(a) Representative seizures elicited by focal pilocarpine injection before (pre-Rx) and after lentiviral treatment with eGluCl or GFP (post-Rx) (scale bar 5min and 1mV). (b) Absolute differences in the cumulative coastline between the two pilocarpine trials pre-Rx and post-Rx (eGluCl –1.08±0.58V at 20 minutes, n=6 animals; GFP 1.04±0.34V, n=7 animals; mean±sem, p=0.007, Student’s t-test). (c) Number of spikes (ratio of spikes in the second trial to the first trial: eGluCl: 0.60±0.12; GFP: 1.27±0.18; mean±sem, p=0.012, Student’s t-test), 4 – 14 Hz power (ratio of second trial to first: eGluCl: 0.44±0.19; GFP: 1.47±0.16; p=0.002), spike frequency (ratio of second trial to first: eGluCl: 0.65±0.13; GFP: 1.29±0.14; p=0.007), and seizure duration post-Rx normalized to the corresponding values pre-Rx (ratio of second trial to first: eGluCl: 0.79±0.11; GFP: 1.02±0.10; p=0.146). *p<0.05; **p<0.01.